The study has used control data from 30 European countries (EU and EEA) by 2015, and researchers have considered 16 different combinations of bacteria and antibiotic resistance. This includes bacteria that are considered common causes of hospital infections and are immediately resistant to antibiotic groups that are considered critical for human medicine.
"The greatest burden of the disease is calculated for countries in southern Europe, while Norway and other Nordic countries are best outside, winning research by Petter Elstrøm in Norway's Public Health Institute, who participated in the study.
The disease that obstructs their resistant bacteria has increased the level of significance over the past eight years, and the largest adds one among the Klebsiella pneumoniae and Escherichia coli-resistant infections. 75 percent of the disease can be associated with hospitalized infections and 39 percent of obese gram-negative bacteria that are resistant to the latest antibiotic lines such as carbapenem and colistin. This leads to the fact that there are few or no effective antibiotics that can be used against infections caused by these bacteria.
It is estimated that nearly 1 900 people in Norway in the quarter each year receive an infection of resistant bacteria involved in the study. This causes about 69 additional deaths due to bacteria resistant to antibiotics. Elstrøm points out that the calculations in the study are good with the good control data we have in Norway.
– One resistant bacterium has good monitoring data in methicillin-resistant Staphilococcus aureus (MRSA) in Norway. The study estimates that 17 people in the year get blood infections with MRSA. 11 people with such MRSA infections have been registered in the Norwegian contagious disease surveillance system (MSIS) for 2015. Since the cause of the infection has not always been identified, I would like to say that the results in the study correspond to the control data we have in Norway, both for MRSA infections and for other infections of resistant bacteria reported to MSIS, Elstrøm says.
For the first time, the burden of bacteria-resistant antibiotics is also measured in the form of DALI (a lifetime adjusted to calming). DALI is a target for a disease that has been coughing many years lost as a result of reduced health, functional ability and premature death. DALI is often used to compare the burden of various diseases or to compare cargo between countries and different groups of people. DALI can and can estimate the cost of the disease burden. Such cost analysis is done in a standardized way to compare costs associated with different countries.
– The study calculates that the burden of disease-resistant bacteria is around 1,700 DALIs in Norway. Converted to the crown and ear, the burden of diseases of their resistant bacteria causes the annual cost of a society of about 2 billion Norwegian crowns, "Elstrøm notes.
The Organization for Economic Co-operation and Development (OECD) uses the results of this study to more accurately calculate the economic burden associated with resistant bacteria. This is published in a special OECD report, referring to Superbug Tide, published on November 7th this year.
Even if the burden of the disease is significant and increased in Europe, it is still possible to do a softening to reverse the development.
– The most important options we can do in Norway and globally are the reduction of antibiotic consumption. In addition, we must ensure that good contamination measures prevent the spread of resistant bacteria and contribute to the research and development of new types of antibiotics, Elstrøm says.
Significant deaths and lifetimes adapted to developmental disorders caused by antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: the analysis of population-based modeling (The Lancet)
Health services related infection, antibiotic use (NOIS), antibiotic resistance (MSIS) and World Day of Hand Hygiene. Annual Report 2017 (Norwegian Institute of Public Health)
European Antibiotic Day (ECDC)